Stock listing

Stuttgart:7XB0 Xbrane Biopharma AB Aktie

German listing (Stuttgart) of Xbrane Biopharma AB · home listing Stockholm:XBRANE

Follow Xbrane Biopharma AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:XBRANE

11.40 SEK +0.20 (+1.8%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:XBRANE

Since Jul 6, 2026 +8.6% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
11.00 – 11.55 SEKOct 16, 2026
Volume
28,248 sharesOct 16, 2026
Market value
234.9M SEKAt the close on Oct 16, 2026 · price × 20.61M shares outstanding
Xbrane Biopharma AB logo
Ticker
Stuttgart:7XB0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stuttgart
Currency
EUR

What changed lately

Calls

Replays

  • Xbrane Biopharma (Stockholm:XBRANE) Q2 2026 Earnings Call

    Fri, Jul 17, 2026 · 3:00 AM ET

    Watch Transcript

  • Xbrane Biopharma (Stockholm:XBRANE) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 3:00 AM ET

    Watch Transcript

  • Xbrane Biopharma (Stockholm:XBRANE) Q4 2025 Earnings Call

    Fri, Feb 20, 2026 · 7:00 AM ET

    Watch Transcript

Latest news

Xbrane Biopharma releases Interim Report for January-June 2026

Jul 17, 2026

Xbrane Biopharma AB and JOINN Biologics US Inc. Enter Strategic Partnership to Develop Xdarzane – Xbrane´s Biosimilar Candidate to Darzalex® (Daratumumab)

Jun 11, 2026

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)

Jun 3, 2026

Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities

May 5, 2026

XBRANE submits ranibizumab biosimilar candidate to FDA

Apr 30, 2026

Xbrane provides an update on the timeline for resubmission of the market authorization application in the United States

Mar 31, 2026

Xbrane has released the company's 2025 Annual and Sustainability Report. The report summarizes business, financial performance and work on sustainability.

Mar 31, 2026

Xbrane Biopharma releases Year-end Report 2025

Feb 20, 2026

Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution

Nov 24, 2025

XBRANE updates on timing for resubmission of the BLA for its ranibizumab biosimilar candidate to FDA

Nov 19, 2025

All Xbrane Biopharma AB news

Decks

Xbrane Biopharma AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
12 in the last 12 months · 12 in all · newest Jul 17, 2026 · oldest 2025
Calls
10 calls with a replay · 10 with a transcript · latest Jul 17, 2026
Decks
6 decks · latest Jul 17, 2026

Where Xbrane Biopharma AB is listed

ListingExchangeCountryCurrency
Stockholm:XBRANE · Home listingStockholmSwedenSEK
gettex:7XB0gettexGermanyEUR
LS Exchange:A41PJJLS ExchangeGermanyEUR
Lang & Schwarz:A41PJJLang & SchwarzGermanyEUR
Aquis:XBRANSAquisUnited KingdomSEK
Aquis:XBRANSAquisUnited KingdomSEK
Frankfurt:7XB0FrankfurtGermanyEUR
Munich:7XB0MunichGermanyEUR
Stuttgart:7XB0 · This pageStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Xbrane Biopharma AB.